Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 11Gastrointestinal 6Other 4Lymphoid 4Dermatologic 4Genitourinary 3Thoracic 2Other hematologic neoplasm 2Plasma cell 1Other neoplasm 1Head & Neck 1CNS 1

Conditions

Melanoma 3Skin Neoplasms 1Dermatitis, Contact 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Docosahexaenoic Acids × Dermatologic × Clear all
NCT00244816 2025-10-23

Taxoprexin® Treatment for Advanced Eye Melanoma

American Regent, Inc.

Phase 2 Completed
22 enrolled
Dermatologic

Melanoma

NCT00249262 2025-09-26

Taxoprexin Treatment for Advanced Skin Melanoma

American Regent, Inc.

Phase 2 Completed
30 enrolled
Dermatologic

Melanoma

NCT00087776 2025-07-23

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

American Regent, Inc.

Phase 3 Terminated
393 enrolled
Dermatologic

Melanoma

NCT01032343 2013-08-22

An Immunonutritional Approach to the Prevention of Skin Cancer

University of Manchester

Phase NA Completed
90 enrolled
Dermatologic

Dermatitis, Contact, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡